228 related articles for article (PubMed ID: 22214649)
1. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.
Muly EC; Votaw JR; Ritchie J; Howell LL
J Pharmacol Exp Ther; 2012 Apr; 341(1):81-9. PubMed ID: 22214649
[TBL] [Abstract][Full Text] [Related]
2. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?
Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Kodaka F; Okumura M; Otsuka T; Suhara T
J Neurosci; 2009 Oct; 29(43):13730-4. PubMed ID: 19864585
[TBL] [Abstract][Full Text] [Related]
3. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
Ito H; Arakawa R; Takahashi H; Takano H; Okumura M; Otsuka T; Ikoma Y; Shidahara M; Suhara T
Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
6. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
9. Signalling profile differences: paliperidone versus risperidone.
Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA
Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
[TBL] [Abstract][Full Text] [Related]
11. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
[TBL] [Abstract][Full Text] [Related]
13. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.
Marchese G; Pittau B; Casu G; Peddio G; Spada GP; Pira M; Deriu A; Portesani F; Pisu C; Lazzari P; Pani L
Eur Psychiatry; 2010 Mar; 25(2):92-100. PubMed ID: 19640686
[TBL] [Abstract][Full Text] [Related]
14. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
15. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
[TBL] [Abstract][Full Text] [Related]
16. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
17. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2006 Sep; 31(9):1991-2001. PubMed ID: 16738543
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
19. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
